Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-600-7373
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
OptionableOptionable
Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions
What is Minerva Neurosciences' stock symbol?
Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How were Minerva Neurosciences' earnings last quarter?
Minerva Neurosciences Inc (NASDAQ:NERV) announced its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.07. View Minerva Neurosciences' Earnings History.
When is Minerva Neurosciences' next earnings date?
What price target have analysts set for NERV?
0 Wall Street analysts have issued 12-month price targets for Minerva Neurosciences' shares. Their predictions range from $19.00 to $19.00. On average, they anticipate Minerva Neurosciences' share price to reach $19.00 in the next year. This suggests a possible upside of 174.2% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences.
Has Minerva Neurosciences been receiving favorable news coverage?
News coverage about NERV stock has trended negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Minerva Neurosciences earned a news impact score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Who are some of Minerva Neurosciences' key competitors?
Some companies that are related to Minerva Neurosciences include Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB) and ImmunoGen (IMGN).
Who are Minerva Neurosciences' key executives?
Minerva Neurosciences' management team includes the folowing people:
- Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
- Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
- Dr. Michael Davidson, Chief Medical Officer (Age 69)
- Mr. Richard Russell, Pres (Age 55)
- Mr. Joseph Reilly, Sr. VP & COO (Age 44)
Who are Minerva Neurosciences' major shareholders?
Minerva Neurosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.03%). Company insiders that own Minerva Neurosciences stock include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View Institutional Ownership Trends for Minerva Neurosciences.
Which major investors are buying Minerva Neurosciences stock?
NERV stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Minerva Neurosciences stock in the last two years include Marc D Beer and William F Doyle. View Insider Buying and Selling for Minerva Neurosciences.
How do I buy shares of Minerva Neurosciences?
Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Minerva Neurosciences' stock price today?
One share of NERV stock can currently be purchased for approximately $6.93.
How big of a company is Minerva Neurosciences?
Minerva Neurosciences has a market capitalization of $269.37 million. The biopharmaceutical company earns $-31,520,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Minerva Neurosciences employs 12 workers across the globe.
What is Minerva Neurosciences' official website?
How can I contact Minerva Neurosciences?
Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]
MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days.
